Market
Overview
The
Inflammatory Bowel Disease Treatment Market Insights And Analysis by Drug Class (TNF Inhibitors,
Aminosalicylates) Disease Indication (Ulcerative Colitis, Crohn’s Disease)
Distribution Channel (Hospital Pharmacy), End-User (Hospitals &
Clinics)—Forecast till 2030
During
the forecast period, the Inflammatory
Bowel Disease Treatment Market is expected to grow
at a CAGR of 5%. Over the next few years, the market is likely to increase
because ulcerative disease and Crohn's disease are becoming more common around
the world. In the coming years, the market is expected to grow because more
people are using biologics to treat and because there are strong pipeline drugs
like risankizumab, upadacitinib, tofacitinib, ustekinumab, and others. The
COVID-19 pandemic didn't have much effect on the market in 2020. However, many
countries have seen a drop in the number of people being diagnosed with
inflammatory bowel disease because of the complete lockdown.
Market
Segmentation
The
market is split into two groups based on the diseases they treat: ulcerative
colitis and Crohn's disease.
People
with Crohn's disease are expected to make up the largest part of the market.
This segment is growing because Crohn's disease is becoming more common and
because more people around the world are getting treatment for Crohn's disease.
The
injectables market is expected to grow because of factors like the growing use
of biologics to treat ulcerative colitis and Crohn's disease and the growth of
product approvals for biologics.
The
market has been split by drug
class into IL inhibitors, JAK inhibitors, TNF inhibitors, anti-integrin, ASA
drugs, corticosteroids, and others.
The
largest part of the market was made up of TNF inhibitors. Patients of
inflammatory bowel disease can use monoclonal antibodies to target remission
and keep it going. This is helping the segment grow in the market.
Regional
Classification
In
2020, North America led the Inflammatory Bowel Disease Treatment Market Trends therapy, with a revenue share of around 60.0%.
During the projection period, the area is anticipated to have profitable
growth. High treatment rates, a rise in the prescription of innovative
pharmaceuticals, and improved reimbursement regulations in the region
contribute to market expansion.
In
addition, rising research and development initiatives to produce better
treatment choices, as well as the presence of large pharmaceutical firms in the
area, are likely to drive market expansion throughout the projection period. As
stated by the U.S. National Library of Medicine, there are a total of 730
clinical studies connected to IBD as of October 2019, 268 of which are being
undertaken only in the United States.
Asia-Pacific
is expected to have a higher CAGR because more people are becoming aware of
ulcerative colitis and Crohn's disease there. In addition, more and more drugs
are being approved to treat these diseases.
Industry
News
March
2022 - Pfizer Inc. acquires Arena Pharmaceuticals, a clinical-stage business
developing potential revolutionary treatments for the treatment of a variety of
immuno-inflammatory diseases. This breakthrough assisted the firm in
diversifying its portfolio for a number of immuno-inflammatory disorders,
including ulcerative colitis, Crohn's disease, and others.
Bristol
Myers Squibb announced in May 2021 that the Food and Drug Administration had
authorized Zeposia (ozanimod) for the treatment of people with moderate to
severely active ulcerative colitis.
STELARA
was authorized to treat mild to severely active ulcerative colitis in the EU in
September 2019.
At Market
Research Future (MRFR), we enable our customers to unravel the complexity of
various industries through our Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective
to provide the optimum quality market research and intelligence services to our
clients.
Contact us:
Market Research
Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,
5Th Floor,
New York, New
York 10013
United States of
America
+1 628 258 0071
Email: sales@marketresearchfuture.com
0 Comments